Targeting the P2X7 receptor in rheumatoid arthritis: biological rationale for P2X7 antagonism

CER7121
2014 Vol.32, N°6
PI 0878, PF 0882
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 25288220 [PubMed]

Received: 07/11/2013
Accepted : 11/04/2014
In Press: 07/10/2014
Published: 09/12/2014

Abstract

OBJECTIVES:
This paper aims to explore the functional significance of the P2X7 receptor in preclinical models of rheumatoid arthritis.
METHODS:
Preclinical studies in vivo were performed using the rat streptococcal cell wall (SCW) arthritis model. Ex vivo cultures of lipopolysaccharide (LPS)/benzoylbenzoyl adenosine triphosphate (BzATP)-stimulated human monocytes were generated to test the activities of a novel, highly specific inhibitor of human P2X7, AZD9056, on interleukin (IL)-1 and IL-18 release.
RESULTS:
P2X7 receptor expression was detected in inflamed synovial tissue after onset of SCW-induced arthritis in rats. Inhibition of P2X7 therein led to reduced articular inflammation and erosive progression. No effect was noted on acute-phase responses. Ex vivo, AZD9056 inhibited IL-1 and IL-18 release to BzATP in LPS-primed human monocytes.
CONCLUSIONS:
P2X7 receptor inhibition could represent a novel approach to the treatment of inflammatory arthritis. However, confirmatory clinical studies are warranted to further explore this possibility.